ASCO 2026 Highlights – Part 2: Emerging Immunotherapy Strategies in Lung Cancer
Lung Cancer ConsideredShow Notes
In Part 2 of the ASCO 2026 Highlights series, hosts Dr. Narjust Florez and Dr. Stephen Liu are joined by Dr. Julie Brahmer and Dr. Solange Peters to discuss some of the most notable immunotherapy advances presented at the 2026 ASCO Annual Meeting. The conversation explores emerging data for PD-1/VEGF and PD-L1/VEGF bispecific antibodies, the growing role of antibody-drug conjugates in combination with immunotherapy, and promising new strategies targeting KRAS-mutant lung cancers, highlighting how these approaches may reshape the future treatment landscape.
Guests:
Julie R. Brahmer, MD, MSc, FASCO, FAIO The Marilyn Meyerhoff Professor of Thoracic Oncology Co-Leader, Cancer Immunology Research Program Co-Director, Upper Aerodigestive Cancers Program Director, Johns Hopkins Kimmel Cancer Center, Bayview Campus
Professor Solange Peters, MD, PhD Chair of Medical Oncology Director of Oncology Department - CHUV Lausanne University Hospital
More from Lung Cancer Considered
The 2026 World Conference on Lung Cancer brought together leading experts, researchers, and oncologists to showcase the latest advancements in lung cancer research. To reach a global audience, IASLC has recorded podcast episodes on WCLC 2026 in world languages.
The 2026 World Conference on Lung Cancer brought together leading experts, researchers, and oncologists to showcase the latest advancements in lung cancer research. To reach a global audience, IASLC has recorded podcast episodes on WCLC 2026 in world languages.
The 2026 World Conference on Lung Cancer brought together leading experts, researchers, and oncologists to showcase the latest advancements in lung cancer research. To reach a global audience, IASLC has recorded podcast episodes on WCLC 2026 in world languages.
Recorded at the 2026 IASLC World Conference on Lung Cancer in Seoul, this special Early Career Takeover episode explores what this annual meeting offers to researchers and clinicians at the start of their careers.
The WHO Eastern Mediterranean Region (EMRO) faces unique challenges around exposures, non-conventional smoking, lung cancer screening, molecular profiling, and evolving therapies in lung cancer. To address this, the inaugural joint IASLC/EMRO workshop took place at the 2026 World Conference on Lung Cancer (WCLC) in Seoul.